Cell Genesys (CEGE) Inactive 10-K2003 FY Annual report

Filed: 4 Mar 04, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: abandon, abide, Academy, adherence, advertise, advertising, advice, AG, alliance, ALS, Amyotrophic, analyzed, ancillary, ASCO, assistant, asymptomatic, borrowed, bronchoalveolar, built, CancerVax, Carol, cGMP, chance, circulating, civil, collagen, configuration, context, conveniently, Cosmetic, costly, criminal, cytokine, DEA, death, dendritic, destruction, detention, diagnosed, dialogue, died, discovery, Distinguished, dying, easier, educational, element, eventual, frequency, Gehrig, Gleason, global, Grundfest, GTI, halt, ICTP, identical, imposition, inflammatory, inItem, inNote, intercompany, Jackson, leukemic, Lou, man, mandatory, marker, marketplace, maximize, Medarex, melanoma, men, metastasized, overlap, pain, people, population, pre, precautionary, prevailing, procurement, promote, promoter, promotion, promotional, prostatectomy, quantity, question, radiologic, radiologically, reassessment, redeploy, redeployment, redesign, regimen, residual, reverse, revised, revocation, Roche, Salk, sample, Satisfaction, score, seeNote, seismically, seize, seizure, semiautomated, serial, Silicon, simulate, sought, Squibb, stabilization, sterility, submission, subtype, sum, surveillance, susceptible, suspend, suspended, suspension, symptomatic, systematic, Systemix, taxane, team, telomerase, telopeptide, terrorism, testosterone, theManagement, timeframe, turn, twelve, unanticipated, uncertainty, undertaken, underway, unfavorable, unforeseen, unknown, unreasonable, upward, Valley, voluntarily, voluntary, waived, waiver, warning, website, widespread, wind, withdraw, withdrawal, withItem

Removed: AAV, adenoviral, adjusted, Alameda, allogeneic, applied, approximate, arrangement, asset, assuming, Bulletin, Calyx, cardiovascular, chimeric, consisting, constructed, delivered, delivering, discussed, diseased, efficient, ending, EntreMed, Exercised, formation, forward, Fred, Gage, GMP, immunity, impacted, innovative, intradermal, IPO, Kucherlapati, lethally, liver, marketability, met, mixed, modification, Municipal, muscle, nondividing, note, Overview, par, participate, partnering, pertaining, policy, positive, potency, preferable, Prepaid, preventative, prevented, principle, produced, prolonged, Raju, receptor, registrant, relapse, representing, restructuring, retroactive, SAB, scan, selection, serve, shelter, smaller, Specifically, staffed, substance, sustain, tenant, toxicity, transplant, trend, vivo

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

CEGE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Stephen A. Sherwin, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Cell Genesys, Inc. on Form 10-K for the year ended December 31, 2003 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-K fairly presents in all material respects the financial condition and results of operations of Cell Genesys, Inc.

Dated: March 4, 2004



By:		/s/ STEPHEN A. SHERWIN, M.D

		Name: Stephen A. Sherwin, M.D. Title: Chairman of the Board and Chief Executive Officer

I, Matthew J. Pfeffer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report of Cell Genesys, Inc. on Form 10-K for the year period ended December 31, 2003 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-K fairly presents in all material respects the financial condition and results of operations of Cell Genesys, Inc.

Dated: March 4, 2004



By:		/s/ MATTHEW J. PFEFFER

		Name: Matthew J. Pfeffer Title: Vice President and Chief Financial Officer